General information | DisProt: | DP00471 | Name: | Lipoprotein | Synonym(s): | Q6QCC2_NEIME
Lipoprotein GNA1870
| First appeared in release: | Release 3.1 (03/31/2006) | UniProt: | Q6QCC2 | UniGene: | | SwissProt: | Q6QCC2_NEIME | TrEMBL: | | NCBI (GI): | 75369663 | Source organism: | Neisseria meningitidis | Sequence length: | 274 | Percent disordered: | 13% | Homologues: | |
Native sequence |
10 20 30 40 50 60 | | | | | | MNRTAFCCLS LTTALILTAC SSGGGGVAAD IGAGLADALT APLDHKDKGL QSLTLDQSVR - 60 KNEKLKLAAQ GAEKTYGNGD SLNTGKLKND KVSRFDFIRQ IEVDGQLITL ESGEFQVYKQ - 120 SHSALTAFQT EQIQDSEHSG KMVAKRQFRI GDIAGEHTSF DKLPEGGRAT YRGTAFGSDD - 180 AGGKLTYTID FAAKQGNGKI EHLKSPELNV DLAAADIKPD GKRHAVISGS VLYNQAEKGS - 240 YSLGIFGGKA QEVAGSAEVK TVNGIRHIGL AAKQ
|
Functional narrative |
Neisseria meningitidis is a human pathogen implicated with sepsis and meningitis in children and young adults. Capsular polysaccharide-based vaccines have been produced for four out of the five major meningococcal serogroups associated with invasive disease (A, C, Y and W135). Unfortunately, the capsular polysaccharide of serogroup B is poorly immunogenic, making this type of vaccine ineffective. As an alternative strategy, reverse vaccinology was exploited for the identification of novel surface-exposed protein antigens to be used in a vaccine formulation against Meningococcus B. Among them, genome-derived Neisseria antigen 1870 (GNA1870) is a lipoprotein of unknown function. In vitro and in vivo
assays showed that GNA1870 is expressed on the surface of Meningococcus, is able to elicit good levels of antibodies with bactericidal activity, and induces passive protection in the infant rat model. Three variants of the protein can be distinguished, with levels of sequence similarity ranging from 62.8% between variant 1 and 3, to 74.1% between variant 1 and 2, and 84.7% between variant 2 and 3. Although the three alleles display very low levels of cross-bactericidal response, a vaccine containing representative molecules of the three variants of GNA1870 may be able to protect against all N. meningitidis strains.
|
Map of ordered and disordered regions |
Note: 'Mouse' over a region to see the start and stop residues. Click on a region to see detailed information.
|
Region 1 | Type: | Disordered | Name: | immunodominant C-terminal BC domain, N-terminal end | Location: | 120 - 155 | Length: | 36 | Region sequence: |
QSHSALTAFQTEQIQDSEHSGKMVAKRQFRIGDIAG | Modification type: | Fragment
Native
| PDB: | 1YS5:A | Structural/functional type: | Relationship to function unknown | Functional classes: | | Functional subclasses: | | Detection methods:
- Nuclear magnetic resonance (NMR) (298 K; pH: 7; 1.0 mM protein; 20 mM phosphate)
| References:
- Cantini F, Savino S, Scarselli M, Masignani V, Pizza M, Romagnoli G, Swennen E, Veggi D, Banci L, Rappuoli R. "Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis." J Biol Chem. 2006; 281(11): 7220-7. PubMed: 16407174
| Comments:
|
References |
- Welsch JA, Rossi R, Comanducci M, Granoff DM. "Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine." J Immunol. 2004; 172(9): 5606-15. PubMed: 15100304
|
If you have any comments or wish to provide additional references to this protein or its disordered region(s), please click here to e-mail us. |
Disprot-footer
|